Definium Therapeutics Quarterly Cash Flow Statement
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
36.90+2.72 (+7.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 37.00 +0.27%
Definium Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Definium Therapeutics generated -$52.8 million of operating cash flow. That left free cash flow of -$52.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -158.99M | -77.10M | -50.44M | -67.27M | -42.74M | -23.35M | -34.74M | -13.68M | -5.85M | -54.40M | -23.86M | -17.92M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 9.64M | 7.13M | 5.60M | 5.82M | 5.25M | 3.43M | 3.95M | 3.84M | 5.43M | 3.69M | 3.37M | 4.23M |
| Change in Working Capital | 6.43M | 5.36M | -4.28M | 8.11M | 8.07M | -2.45M | -158.00K | 983.00K | -3.46M | -726.00K | -3.47M | -520.00K |
| Operating Cash Flow | -52.78M | -42.63M | -42.98M | -29.57M | -29.60M | -29.42M | -25.35M | -17.19M | -19.99M | -16.60M | -20.56M | -16.63M |
| Investing Cash Flow | -316.74M | 42.00M | 34.98M | 15.41M | -39.54M | -162.46M | 0 | 0 | 0 | 0 | — | — |
| Financing Cash Flow | 762.27M | 5.31M | 245.87M | 749.00K | 19.65M | 1.00M | 3.81M | 69.35M | 10.79M | 169.25M | 2.59M | 17.40M |
| Net Change in Cash | 392.75M | 4.68M | 237.88M | -13.43M | -49.46M | -190.89M | -21.54M | 52.15M | -9.20M | 152.63M | -18.00M | 804.00K |
| Free Cash Flow | -52.78M | -42.63M | -42.98M | -29.57M | -29.60M | -29.42M | -25.35M | -17.19M | -19.99M | -16.60M | -20.56M | -16.63M |
This table shows 12 quarterly periods of Definium Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 8 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow DFTX's reporting calendar. What is a cash flow statement?